PubMed · 12498013
Eletriptan Pfizer.
Abstract
Pfizer has developed and launched eletriptan, a 5-HT1B/1D agonist, for the potential treatment of migraine with and without aura. Eletriptan has 6-fold greater affinity for the 5-HT1D receptor than sumatriptan, and a 3-fold greater affinity for the 5-HT1B receptor [249570]. Eletriptan pharmacology has also been evaluated in vitro in comparison with zolmitriptan (AstraZeneca plc) and naratriptan (GlaxoSmithKline plc) [290116].
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Paul J L M Strijbos, Andrew A Parsons, Anders Fugelli. 2002. Eletriptan Pfizer.. https://pubmed.ncbi.nlm.nih.gov/12498013/
Cite the original work for its findings. Save a collection to share your selection of sources.